Phase II studies of the glycine antagonist GV150526 in acute stroke: The North American Experience

Stroke

Volumn 31, Issue 2, 2000, Pages 358-365

  Haley Jr , E Clarke ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cerebral infarction; Glutamate antagonists; Neuroprotection; Stroke therapy; Stroke, acute

Indexed keywords

GAVESTINEL; GLYCINE RECEPTOR ANTAGONIST;

ACUTE DISEASE; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION SIZE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0343415042     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.2.358     Document Type: Article

References (18)

1. Choi D. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev. 1990;2:105-147.
2. Albers GW, Atkinson RP, Kelley RE, Rosenbaum MD, on behalf of the Dextrorphan Study Group. Safety, tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 1995;26:254-258.
3. Davis SM, Albers GW, Diener HC, Lees KR, Morris J. Termination of acute stroke studies involving selfotel treatment. Lancet. 1997;349:32. Letter.
4. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 1997;49(suppl 4):S66-S69.
5. Di Fabio R, Capelli AM, Conti N, Cugola A, Donati D, Feriani A, Gastaldi P, Gaviraghi G, Hewkin CT, Micheli F, Missio A, Mugnaini M, Pecunioso A, Quaglia AM, Ratti E, Rossi L, Tedesco G, Trist DG, Reggiani A. Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J Med Chem. 1997;40:841-850.
6. Bordi F, Pietra C, Ziviani L, Reggiani A. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp Neurol. 1997;145:1-10.
7. Dyker AG, Lees KR. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Stroke. 1999;30:986-992.
8. GAIN European Study Group. Safety and tolerability of GV150526 in acute stroke (GLYB2002). Cerebrovasc Dis. 1998;6(suppl. 4):20. Abstract.
9. Lyden P, Brott T, Tilley B, Welch KMA, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J, and the NINDS TPA Stroke Study Group. Improved reliability of the NIH Stroke Scale using video training. Stroke. 1994;25:2220-2226.
10. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
11. van Sweiten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
12. Adams HP Jr, Bendixen BH, Kappelle J, Biller J, Love BB, Gordon DL, Marsh EE, and the TOAST Investigators. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
13. Beal SL, Sheiner LB. NONMEM Users Guide. San Francisco, Calif: University of California at San Francisco, Division of Clinical Pharmacology; 1979-1998.
14. Warach S. Results of the GAIN 2 MRI feasibility study: a substudy of the phase II 2005 safety trial of GV150526. Cerebrovasc Dis. 1999;9(suppl 1):128. Abstract.
15. Wolf PA, D'Agostino RB. Epidemiology of stroke. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis, and Management. New York, NY: Churchill Livingstone; 1998:3-28.
16. Pulsinelli WA, Waldman S, Rawlinson D, Plum F. Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat. Neurology. 1982;32:1239-1246.
17. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ. 1997;314:1303-1306.
18. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, Faught ER, Haley EC, for the RANTTAS Investigators. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. Stroke. 1998;29:447-453.